|
US5585362A
(en)
|
1989-08-22 |
1996-12-17 |
The Regents Of The University Of Michigan |
Adenovirus vectors for gene therapy
|
|
US5804604A
(en)
|
1989-12-21 |
1998-09-08 |
Biogen, Inc. |
Tat-derived transport polypeptides and fusion proteins
|
|
EP0786469B1
(en)
|
1990-06-11 |
2006-03-01 |
Gilead Sciences, Inc. |
Methods of use of nucleic acid ligands
|
|
US5270163A
(en)
|
1990-06-11 |
1993-12-14 |
University Research Corporation |
Methods for identifying nucleic acid ligands
|
|
US5151360A
(en)
|
1990-12-31 |
1992-09-29 |
Biomembrane Institute |
Effect of n,n,n-trimethylsphingosine on protein kinase-c activity, melanoma cell growth in vitro, metastatic potential in vivo and human platelet aggregation
|
|
JP3534749B2
(ja)
|
1991-08-20 |
2004-06-07 |
アメリカ合衆国 |
アデノウイルスが介在する胃腸管への遺伝子の輸送
|
|
US5252479A
(en)
|
1991-11-08 |
1993-10-12 |
Research Corporation Technologies, Inc. |
Safe vector for gene therapy
|
|
FR2688514A1
(fr)
|
1992-03-16 |
1993-09-17 |
Centre Nat Rech Scient |
Adenovirus recombinants defectifs exprimant des cytokines et medicaments antitumoraux les contenant.
|
|
AU680459B2
(en)
|
1992-12-03 |
1997-07-31 |
Genzyme Corporation |
Gene therapy for cystic fibrosis
|
|
ES2249761T3
(es)
|
1993-06-24 |
2006-04-01 |
Advec Inc. |
Vectores de adenovirus para terapia genica.
|
|
EP1637608B1
(en)
|
1993-10-25 |
2009-07-22 |
CANJI, Inc. |
Recombinant adenoviral vector and methods of use
|
|
US5783405A
(en)
|
1994-02-01 |
1998-07-21 |
Terrapin Technologies, Inc. |
Rapid screening method for effectors of signal transduction
|
|
GB9624482D0
(en)
|
1995-12-18 |
1997-01-15 |
Zeneca Phaema S A |
Chemical compounds
|
|
BR9707495A
(pt)
|
1996-02-13 |
1999-07-27 |
Zeneca Ltd |
Derivado de quinazolina processo para a preparação do mesmo composição farmacêutica e processo para a produç o de um efeito antiangiogênico e/ou de redução de permeabilidade vascular em um animal de sangue quente
|
|
US6291455B1
(en)
|
1996-03-05 |
2001-09-18 |
Zeneca Limited |
4-anilinoquinazoline derivatives
|
|
GB9718972D0
(en)
|
1996-09-25 |
1997-11-12 |
Zeneca Ltd |
Chemical compounds
|
|
GB9714249D0
(en)
|
1997-07-08 |
1997-09-10 |
Angiogene Pharm Ltd |
Vascular damaging agents
|
|
US20030073640A1
(en)
|
1997-07-23 |
2003-04-17 |
Ribozyme Pharmaceuticals, Inc. |
Novel compositions for the delivery of negatively charged molecules
|
|
AU3751299A
(en)
|
1998-04-20 |
1999-11-08 |
Ribozyme Pharmaceuticals, Inc. |
Nucleic acid molecules with novel chemical compositions capable of modulating gene expression
|
|
GB9900334D0
(en)
|
1999-01-07 |
1999-02-24 |
Angiogene Pharm Ltd |
Tricylic vascular damaging agents
|
|
GB9900752D0
(en)
|
1999-01-15 |
1999-03-03 |
Angiogene Pharm Ltd |
Benzimidazole vascular damaging agents
|
|
TW440494B
(en)
*
|
1999-05-13 |
2001-06-16 |
Sumitomo Spec Metals |
Machining method of rare earth alloy and manufacture of rare earth magnet using it
|
|
US8202979B2
(en)
|
2002-02-20 |
2012-06-19 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid
|
|
US20050020525A1
(en)
|
2002-02-20 |
2005-01-27 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
|
|
PT1309726E
(pt)
|
2000-03-30 |
2010-03-08 |
Whitehead Biomedical Inst |
Mediadores de interferência por rna específicos de sequência de rna
|
|
NZ522074A
(en)
|
2000-05-31 |
2004-06-25 |
Astrazeneca Ab |
Indole derivatives with vascular damaging activity
|
|
IL153484A0
(en)
|
2000-07-07 |
2003-07-06 |
Angiogene Pharm Ltd |
Colchinol derivatives as angiogenesis inhibitors
|
|
CN1255392C
(zh)
|
2000-07-07 |
2006-05-10 |
安吉奥金尼药品有限公司 |
作为血管生成抑制剂的秋水仙醇衍生物
|
|
US20020150936A1
(en)
|
2000-09-01 |
2002-10-17 |
Leonid Beigelman |
Methods for synthesizing nucleosides, nucleoside derivatives and non-nucleoside derivatives
|
|
DE60144479D1
(https=)
|
2000-09-01 |
2011-06-01 |
Ribozyme Pharm Inc |
|
|
US20040259247A1
(en)
|
2000-12-01 |
2004-12-23 |
Thomas Tuschl |
Rna interference mediating small rna molecules
|
|
WO2002090595A1
(en)
*
|
2001-05-03 |
2002-11-14 |
President And Fellows Of Harvard College |
Methods for modulating an immune response by modulating krc activity
|
|
US20050239731A1
(en)
|
2001-05-18 |
2005-10-27 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of MAP kinase gene expression using short interfering nucleic acid (siNA)
|
|
US20050282188A1
(en)
|
2001-05-18 |
2005-12-22 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of gene expression using short interfering nucleic acid (siNA)
|
|
AU2003234185C1
(en)
|
2002-04-22 |
2009-11-19 |
The Board Of Trustees Of The Leland Stanford Junior University |
Peptide inhibitors of protein kinase C
|
|
AU2003236720A1
(en)
*
|
2002-06-14 |
2003-12-31 |
Altana Pharma Ag |
Substituted diaminopyrimidines
|
|
US7482337B2
(en)
|
2002-11-08 |
2009-01-27 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions
|
|
ATE440087T1
(de)
|
2003-01-30 |
2009-09-15 |
Boehringer Ingelheim Pharma |
2,4-diaminopyrimidinderivate, die sich als inhibitoren von pkc-theta eignen
|
|
US20070142401A1
(en)
|
2003-10-27 |
2007-06-21 |
Novartis Ag |
Indolyl-pyrroledione derivatives for the treatment of neurological and vascular disorders related to beta-amyloid generation and/or aggregation
|
|
JP2007513974A
(ja)
|
2003-12-11 |
2007-05-31 |
ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー |
プロテインキナーゼｃのアイソザイム特異的アンタゴニスト
|
|
TW200533357A
(en)
|
2004-01-08 |
2005-10-16 |
Millennium Pharm Inc |
2-(amino-substituted)-4-aryl pyrimidines and related compounds useful for treating inflammatory diseases
|
|
US7582631B2
(en)
|
2004-01-14 |
2009-09-01 |
Amgen Inc. |
Substituted heterocyclic compounds and methods of use
|
|
WO2006105023A1
(en)
|
2005-03-28 |
2006-10-05 |
Boehringer Ingelheim International Gmbh |
Pyridine derivatives useful as inhibitors of pkc-theta
|
|
CA2633992A1
(en)
|
2005-12-21 |
2007-07-05 |
Boehringer Ingelheim International Gmbh |
Pyrimidine derivatives useful as inhibitors of pkc-theta
|
|
DE102006029447A1
(de)
|
2006-06-21 |
2007-12-27 |
Bayer Schering Pharma Ag |
Oxo-substituierte Imidazo[1,2b]pyridazine, deren Herstellung und Verwendung als Arzneimittel
|
|
US9180118B2
(en)
|
2006-07-18 |
2015-11-10 |
University Of Rochester |
Thiadiazolidinone derivatives
|
|
WO2009062059A2
(en)
*
|
2007-11-08 |
2009-05-14 |
Pharmacopeia, Inc. |
Isomeric purinones and 1h-imidazopyridinones as pkc-theta inhibitors
|
|
US8569337B2
(en)
*
|
2008-07-23 |
2013-10-29 |
Vertex Pharmaceuticals Incorporated |
Tri-cyclic pyrazolopyridine kinase inhibitors
|
|
AU2009274023A1
(en)
|
2008-07-23 |
2010-01-28 |
Vertex Pharmaceuticals Incorporated |
Tri-cyclic pyrazolopyridine kinase inhibitors
|
|
MX2011001319A
(es)
|
2008-08-06 |
2011-04-05 |
Vertex Pharma |
Inhibidores de aminopiridina cinasa.
|
|
WO2010033655A1
(en)
|
2008-09-19 |
2010-03-25 |
Complegen, Inc. |
Compounds and methods for pkc theta inhibition
|
|
ES2555982T3
(es)
|
2009-01-15 |
2016-01-12 |
Rigel Pharmaceuticals, Inc. |
Inhibidores de la proteína quinasa C y usos de los mismos
|
|
EP3825833B1
(en)
|
2009-06-10 |
2022-08-03 |
Hexagon Technology Center GmbH |
Ontological filtering using spatial boundary of 3d objects
|
|
EP2528917B1
(en)
*
|
2010-01-27 |
2016-10-19 |
Vertex Pharmaceuticals Incorporated |
Pyrazolopyridines useful for the treatment of autoimmune, inflammatory or (hyper)proliferative diseases
|
|
JP2013518112A
(ja)
|
2010-01-27 |
2013-05-20 |
バーテックス ファーマシューティカルズ インコーポレイテッド |
ピラゾロピリジンキナーゼ阻害剤
|
|
WO2011094288A1
(en)
|
2010-01-27 |
2011-08-04 |
Vertex Pharmaceuticals Incorporated |
Pyrazolopyrazine kinase inhibitors
|
|
UY34072A
(es)
|
2011-05-17 |
2013-01-03 |
Novartis Ag |
Derivados sustituidos de indol
|